PDS Biotechnology Corporation
PDSB
Rank in Stocks
#21951
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm... PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
Share Price
$1.08
Last synced: 2026-11-09
Market Cap
$60.28M
Change (1 day)
-12.20%
Change (1 year)
1.89%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade PDS Biotechnology Corporation (PDSB)
Category
Healthcare
EPS for PDS Biotechnology Corporation (PDSB)
EPS as of June 2026 TTM: $-0.64
According to PDS Biotechnology Corporation's latest financial reports, its current EPS (TTM) is $-0.64. At the end of 2025 the company had an EPS of $-0.74, an increase over its 2024 EPS of $-1.03.
EPS history for PDS Biotechnology Corporation from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.64 | -13.51% |
| 2025 | $-0.74 | -28.16% |
| 2024 | $-1.03 | -25.90% |
| 2023 | $-1.39 | -2.80% |
| 2022 | $-1.43 | 116.67% |
| 2021 | $-0.66 | -25.84% |
| 2020 | $-0.89 | -38.19% |
| 2019 | $-1.44 | -94.50% |
| 2018 | $-26.16 | -21.84% |
| 2017 | $-33.47 | 24.42% |
| 2016 | $-26.90 | 34.37% |
| 2015 | $-20.02 | 23.96% |
| 2014 | $-16.15 | 77.28% |
| 2013 | $-9.11 | 46.46% |
| 2012 | $-6.22 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,546.88% |
US
|
|
| $-7.07 | 1,004.69% |
US
|
|
| $-5.29 | 726.56% |
AU
|
|
| $12.88 | -2,112.52% |
BE
|
|
| $21.56 | -3,468.75% |
NL
|
Questions about PDS Biotechnology Corporation's earnings per share (EPS)
What is PDS Biotechnology Corporation's earnings per share (EPS)?
PDS Biotechnology Corporation's earnings per share (EPS) over the last twelve months is $-0.64, as of Jun 2026.
What was PDS Biotechnology Corporation's earnings per share (EPS) in 2025?
In 2025, PDS Biotechnology Corporation's earnings per share (EPS) was $-0.74, compared with $-1.03 in 2024.
How has PDS Biotechnology Corporation's earnings per share (EPS) changed since 2020?
From 2020 to 2025, PDS Biotechnology Corporation's earnings per share (EPS) was highest in 2021 ($-0.66) and lowest in 2022 ($-1.43).
How does PDS Biotechnology Corporation's earnings per share (EPS) compare with similar companies?
PDS Biotechnology Corporation's earnings per share (EPS) ($-0.64) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.